Program
OMS1620
A development code.
Its studies are mostly in Adrenal Hyperplasia, Congenital, led by OMass Therapeutics Australia Proprietary.
Furthest: phase 1, since Aug 10, 20261 company-led study, 1 open or runningNext primary completion: May 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| OMass Therapeutics Australia Proprietary | 11 open or running | phase 1since Aug 10, 2026 | Aug 10, 2026 | May 2027phase 1 · NCT07811089 |
Also a collaborator on its studies: omass-therapeutics.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 10, 2026First study: phase 1 study in Adrenal Hyperplasia, CongenitalFirst studyNCT07811089 · 84 planned
Ahead
- May 2027Primary completion: phase 1 study in Adrenal Hyperplasia, CongenitalNCT07811089
TargetBeta
“OMS1620 is an oral small molecule antagonist of the melanocortin 2 receptor (MC2R), the receptor for adrenocorticotrophic hormone (ACTH)”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| atumelnantrule | Vertex Pharmaceuticals | phase 3 | 8 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07811089Adrenal Hyperplasia, Congenital | 1 | Not yet recruiting | May 2027 | 84 |
How it is read
Names in the registry
- “OMS1620”, 1 entry
Codes read as this program: OMS1620.
Conditions, from the studies’ own filings
- Adrenal Hyperplasia, Congenital, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.